Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Dec;74(3):459–464.

Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.

S Bhakdi 1, R Käflein 1, T S Halstensen 1, F Hugo 1, K T Preissner 1, T E Mollnes 1
PMCID: PMC1542007  PMID: 2466593

Abstract

It has been assumed that S-protein (vitronectin) associates with terminal C5b-9 complement complexes only when the latter fail to attach to target lipid bilayers, thereby forming inactive fluid-phase SC5b-9 complexes. Using monoclonal anti-S-protein antibodies, we show here that a minor portion of C5b-9 complexes associated with both homologous and heterologous cells contain S-protein. This conclusion derives from Western blot analyses, from the sedimentation behaviour of solubilized S-protein, and from the fact that the protein co-immunoprecipitates with C5b-9(m). Association of S-protein with C5b-9(m) takes place primarily at the stage of C9-binding. An average of less than or equal to 0.4 moles of S-protein are estimated to be present per mole C5b-9(m). Hence, only a fraction of C5b-9 complexes contain S-protein. The function of cell-bound S-protein is unknown. Haemolytic titrations with purified components failed to demonstrate any protective effect of S-protein on the lysis of sheep or human erythrocytes by C5b-9. S-protein bound to complement-lysed homologous or heterologous cells is readily detectable by conventional immunocytochemical staining. We conclude that differentiation between tissue-deposited fluid-phase C5b-9 and membrane C5b-9 complexes cannot be made on the basis of immunohistological stainings for S-protein alone.

Full text

PDF
462

Images in this article

461Fig. 1
on p.461
462Fig. 2
on p.462
462Fig. 3
on p.462
463Fig. 4
on p.463
463Fig. 5
on p.463

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes D. W., Silnutzer J. Isolation of human serum spreading factor. J Biol Chem. 1983 Oct 25;258(20):12548–12552. [PubMed] [Google Scholar]
  2. Barnes D. W., Silnutzer J., See C., Shaffer M. Characterization of human serum spreading factor with monoclonal antibody. Proc Natl Acad Sci U S A. 1983 Mar;80(5):1362–1366. doi: 10.1073/pnas.80.5.1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bhakdi S., Ey P., Bhakdi-Lehnen B. Isolation of the terminal complement complex from target sheep erythrocyte membranes. Biochim Biophys Acta. 1976 Feb 6;419(3):445–457. doi: 10.1016/0005-2736(76)90258-3. [DOI] [PubMed] [Google Scholar]
  4. Bhakdi S., Jenne D., Hugo F. Electroimmunoassay-immunoblotting (EIA-IB) for the utilization of monoclonal antibodies in quantitative immunoelectrophoresis: the method and its applications. J Immunol Methods. 1985 Jun 12;80(1):25–32. doi: 10.1016/0022-1759(85)90160-7. [DOI] [PubMed] [Google Scholar]
  5. Bhakdi S., Muhly M. A simple immunoradiometric assay for the terminal SC5b-9 complex of human complement. J Immunol Methods. 1983 Feb 25;57(1-3):283–289. doi: 10.1016/0022-1759(83)90088-1. [DOI] [PubMed] [Google Scholar]
  6. Bhakdi S., Roth M. Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum. J Immunol. 1981 Aug;127(2):576–580. [PubMed] [Google Scholar]
  7. Bhakdi S., Tranum-Jensen J. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore. J Immunol. 1986 Apr 15;136(8):2999–3005. [PubMed] [Google Scholar]
  8. Bhakdi S., Tranum-Jensen J. Damage to mammalian cells by proteins that form transmembrane pores. Rev Physiol Biochem Pharmacol. 1987;107:147–223. doi: 10.1007/BFb0027646. [DOI] [PubMed] [Google Scholar]
  9. Bhakdi S., Tranum-Jensen J. Membrane damage by complement. Biochim Biophys Acta. 1983 Aug 11;737(3-4):343–372. doi: 10.1016/0304-4157(83)90006-0. [DOI] [PubMed] [Google Scholar]
  10. Bhakdi S., Tranum-Jensen J. Terminal membrane C5b-9 complex of human complement: transition from an amphiphilic to a hydrophilic state through binding of the S protein from serum. J Cell Biol. 1982 Sep;94(3):755–759. doi: 10.1083/jcb.94.3.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Biesecker G. Membrane attack complex of complement as a pathologic mediator. Lab Invest. 1983 Sep;49(3):237–249. [PubMed] [Google Scholar]
  12. Biesecker G., Müller-Eberhard H. J. The ninth component of human complement: purification and physicochemical characterization. J Immunol. 1980 Mar;124(3):1291–1296. [PubMed] [Google Scholar]
  13. Couser W. G., Baker P. J., Adler S. Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int. 1985 Dec;28(6):879–890. doi: 10.1038/ki.1985.214. [DOI] [PubMed] [Google Scholar]
  14. Falk R. J., Podack E., Dalmasso A. P., Jennette J. C. Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol. 1987 Apr;127(1):182–190. [PMC free article] [PubMed] [Google Scholar]
  15. Hayman E. G., Engvall E., A'Hearn E., Barnes D., Pierschbacher M., Ruoslahti E. Cell attachment on replicas of SDS polyacrylamide gels reveals two adhesive plasma proteins. J Cell Biol. 1982 Oct;95(1):20–23. doi: 10.1083/jcb.95.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hayman E. G., Pierschbacher M. D., Ohgren Y., Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4003–4007. doi: 10.1073/pnas.80.13.4003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hugo F., Jenne D., Bhakdi S. Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement. Biosci Rep. 1985 Aug;5(8):649–658. doi: 10.1007/BF01116996. [DOI] [PubMed] [Google Scholar]
  18. Hugo F., Krämer S., Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid-phase SC5b-9 complex of human complement. J Immunol Methods. 1987 May 20;99(2):243–251. doi: 10.1016/0022-1759(87)90134-7. [DOI] [PubMed] [Google Scholar]
  19. Jenne D., Hugo F., Bhakdi S. Monoclonal antibodies to human plasma protein X alias complement S-protein. Biosci Rep. 1985 Apr;5(4):343–352. doi: 10.1007/BF01116907. [DOI] [PubMed] [Google Scholar]
  20. Jenne D., Stanley K. K. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J. 1985 Dec 1;4(12):3153–3157. doi: 10.1002/j.1460-2075.1985.tb04058.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kolb W. P., Muller-Eberhard H. J. The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex. J Exp Med. 1975 Apr 1;141(4):724–735. [PMC free article] [PubMed] [Google Scholar]
  22. Mollnes T. E., Harboe M. Immunohistochemical detection of the membrane and fluid-phase terminal complement complexes C5b-9(m) and SC5b-9. Consequences for interpretation and terminology. Scand J Immunol. 1987 Oct;26(4):381–386. doi: 10.1111/j.1365-3083.1987.tb02270.x. [DOI] [PubMed] [Google Scholar]
  23. Müller-Eberhard H. J. The membrane attack complex of complement. Annu Rev Immunol. 1986;4:503–528. doi: 10.1146/annurev.iy.04.040186.002443. [DOI] [PubMed] [Google Scholar]
  24. Podack E. R., Müller-Eberhard H. J. Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol. 1978 Sep;121(3):1025–1030. [PubMed] [Google Scholar]
  25. Preissner K. T., Müller-Berghaus G. S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S protein with heparin. Eur J Biochem. 1986 May 2;156(3):645–650. doi: 10.1111/j.1432-1033.1986.tb09626.x. [DOI] [PubMed] [Google Scholar]
  26. Preissner K. T., Wassmuth R., Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J. 1985 Oct 15;231(2):349–355. doi: 10.1042/bj2310349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schäfer H., Mathey D., Hugo F., Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol. 1986 Sep 15;137(6):1945–1949. [PubMed] [Google Scholar]
  28. Shaffer M. C., Foley T. P., Barnes D. W. Quantitation of spreading factor in human biologic fluids. J Lab Clin Med. 1984 May;103(5):783–791. [PubMed] [Google Scholar]
  29. Steckel E. W., York R. G., Monahan J. B., Sodetz J. M. The eighth component of human complement. Purification and physicochemical characterization of its unusual subunit structure. J Biol Chem. 1980 Dec 25;255(24):11997–12005. [PubMed] [Google Scholar]
  30. Tschopp J., Masson D., Schäfer S., Peitsch M., Preissner K. T. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities. Biochemistry. 1988 May 31;27(11):4103–4109. doi: 10.1021/bi00411a029. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES